[Previous] Enterprise UI Summit Profile: Adobe’s Matthias Zeller...

 [Next] Top Quark Mass Measurements at the Tevatron...

Some related posts from Technorati and Google.

[Health Care Tips] Quark Pharmaceuticals Announces First Patient Dosing By Pfizer In ...: In addition, Pfizer’s interest demonstrates the viability of RTP801 as a potential target for ophthalmic indications. We look forward to continuing our relationship with Pfizer throughout later stages of clinical development and intend to fully collaborate towards the potential commercialization of PF-4523655 in diabetic macular edema, age-related macular degeneration, and other ophthalmic indications covered in our agreement.”

[Eye Care and Health Information] Quark Pharmaceuticals Announces First Patient Dosing By Pfizer In ...: Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME). PF-4523655 is a novel siRNA drug candidate being co-developed by Quark and Pfizer.

[Health Knowledges] Quark Pharmaceuticals Announces First Patient Dosing By Pfizer In ...: partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating. PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME).

 [Latest Medical Technology from Bio-Medicine.Org] Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer ...: In December 2004 Quark and Silence Therapeutics AG signed aCollaboration Agreement on the development of siRNA molecules for the genetarget RTP-801, which resulted in RTP801i-14, a 19 base pairs longblunt-ended AtuRNAi (siRNA) molecule and also provided Quark with a licenseto AtuRNAi technology. In addition a second agreement (Option and LicenseAgreement) was signed in April 2005, and expanded in 2007, to provide Quarkwith options for non-exclusive licenses to develop additional moleculesagains

 [Bionity.COM News] Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer ...: In December 2004 Quark and Silence Therapeutics AG signed a Collaboration Agreement on the development of siRNA molecules for the gene target RTP-801, which resulted in RTP801i-14, a 19 base pairs long blunt-ended AtuRNAi (siRNA) molecule and also provided Quark with a license to AtuRNAi technology. In addition a second agreement (Option and License Agreement) was signed in April 2005 and expanded in 2007 to provide Quark with options for non-exclusive licenses to develop additional molecules against further specific targets using Silence Therapeutics' proprietary AtuRNAi technology.

 [biospace.com Featured News] Quark Pharmaceuticals Inc. Announces First Patient Dosing by ...: In addition, Pfizer's interest demonstrates the viability of RTP801 as a potential target for ophthalmic indications. We look forward to continuing our relationship with Pfizer throughout later stages of clinical development and intend to fully collaborate towards the potential commercialization of PF-4523655 in diabetic macular edema, age-related macular degeneration, and other ophthalmic indications covered in our agreement."

[Lasik Online Central] Quark Pharmaceuticals Announces First Patient Dosing By Pfizer In ...: Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME). …

Reflected tags on Technorati: Blog, Quark, Graphic Design Blog